XMetA is a novel partial activator of the human insulin receptor. It is designed to provide long-acting reduction of hyperglycemia in patients with Type 2 diabetes, potentially reducing the number of insulin injections needed to control blood glucose levels.
These fully human, high-affinity, allosteric monoclonal antibodies selectively modulate the insulin receptor (INSR). Structurally unrelated to insulin, XMetA antibodies bind the INSR at a different site than insulin and do not significantly interfere with insulin binding. This drug candidate has utility countering hyperglycemia and may be used alone or in combination with insulin or other approved therapies for treating diabetic conditions.
